Darolutamide

Genitourinary Cancers

Spanish Oncology Genito-Urinary GroupSmall moleculeActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

15 Active assets in the Genitourinary Cancers cohort.

Asset / Sponsor	Phase	Rating
Tadalafil Regina Elena Cancer Institute	Phase 3	B
Nivolumab Spanish Oncology Genito-Urinary Group	Phase 2	B
Ipilimumab Dana-Farber Cancer Institute	Phase 2	B
Atezolizumab British Columbia Cancer Agency	Phase 2	B
Riluzole University of California, Irvine	Phase 2	CCC

View all 31 →

Same molecule, other indications

Darolutamide is also rated in:

castration-resistant prostate carcinomaDormant

BBB

Indicative ·

78 / 100

breast cancerDormant

BBB

Indicative ·

73 / 100

castration-resistant prostate carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.